Group 1 - Eli Lilly and Company and Novo Nordisk A/S are key players in the pharmaceutical market, particularly in diabetes and obesity treatments [1] - Eli Lilly reported a significant increase in revenue, driven by strong sales of its diabetes drug, Mounjaro, which has seen a 50% year-over-year growth [1] - Novo Nordisk continues to dominate the GLP-1 receptor agonist market, with a market share of approximately 70%, benefiting from the rising demand for obesity treatments [1] Group 2 - The overall market for diabetes and obesity medications is projected to grow substantially, with estimates suggesting it could reach $100 billion by 2025 [1] - Both companies are investing heavily in research and development to expand their product lines and maintain competitive advantages in the market [1] - Regulatory approvals and clinical trial successes are critical factors influencing the growth trajectories of Eli Lilly and Novo Nordisk [1]